Efgartigimod in the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A Short Communication

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare yet debilitating neuropathy characterized by chronic inflammation, demyelination, and axonal degeneration. Current treatments, including corticosteroids, intravenous immunoglobulins, subcutaneous immunoglobulins, and plasma exchange, often result in inadequate responses and relapse. Efgartigimod, a novel Fc receptor (FcRn) blocker, has emerged as a promising therapy by reducing pathogenic autoantibodies. Recent clinical trials, particularly the ADHERE and ADVANCE-CIDP studies, demonstrate its efficacy in prolonging clinical response and reducing relapse rates. This review explores CIDP’s pathogenesis, current treatments, and the potential of efgartigimod to revolutionize the management of this challenging condition.